Emraclidine (CVL-231) is a selective positive allosteric modulator (PAM) of the cholinergic M4 muscarinic receptor (GCPR) and is the only selective M4 PAM in clinical development . The molecule was highlighted by Cerevel at JPM ‘23 as it has shown promising early results in schizophrenia with several Ph. II trials enrolling ( [...]
5 minute read
Jan. 28, 2023
Emraclidine: A Pioneering M4 Positive Allosteric Modulator
emraclidine
M4 positive allosteric modulator Ph. II for schizophrenia discovery not disclosed Lancet, December 17, 2022 Cerevel Therapeutics, Cambridge, MA